Inflammasome genes polymorphisms and susceptibility to gout. Is there a link?
Por:
Clavijo-Cornejo D., López-Reyes A., Cruz-Arenas E., Jacobo-Albavera L., Rivera-Tlaltzicapa D., Francisco-Balderas A., Domínguez-Pérez M., Romero-Morelos P., Vázquez-Mellado J., Silveira L.H., Pineda C., Martínez-Nava G., Gutierrez M.
Publicada:
1 ene 2022
Categoría:
Medicine (miscellaneous)
Resumen:
Background: The inflammatory response in gout disease is induced by the activation of NLR family pyrin domain-containing 3 (NLPR3) signaling pathway mediated by IL-1ß release. Objective: The objective of the study was to determine the association between single nucleotide polymorphisms (SNPs) within NLRP3 inflammasome genes and gout susceptibility. Methods: Mexican patients with gout from the National Rehabilitation Institute and General Hospital of Mexico were enrolled. A healthy control group was also included. We analyzed the frequency and allelic distribution of eight SNPs from seven different genes within the NLRP3 inflammasome signaling pathway: TLR4 rs2149356, CD14 rs2569190, NLRP3 rs3806268, NLRP3 rs10754558, CARD8 rs2043211, IL-1ß rs1143623, P2RX7 rs3751142, and PPARGC1B rs45520937 SNPs. Results: We found that the SNP rs45520937 of PPARGC1B was associated with the risk of developing gout when it was analyzed using the dominant model (Odds ratio [OR] = 2.30; 95% confidence interval [CI]: 1.09-4.86; p = 0.030), and it is proposed that the adaptor molecule CD14 rs2569190 polymorphism could be associated with a lower risk of gout under an additive model (OR= 0.41;95% CI: 0.16-1.05; p = 0.064). No significant associations were identified for the remaining SNPs. Conclusion: Our findings suggest that the PPARGC1B rs45520937 SNP is associated with gout susceptibility.
Filiaciones:
Clavijo-Cornejo D.:
Division of Musculoskeletal and Rheumatic Diseases, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra IbarraMexico City, Mexico
López-Reyes A.:
Gerosciences Laboratory, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra IbarraMexico City, Mexico
Cruz-Arenas E.:
Hospital Epidemiological Surveillance Unit, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra IbarraMexico City, Mexico
Jacobo-Albavera L.:
Laboratory of Cardiovascular Genomics, Instituto Nacional de Medicina GenómicaMexico City, Mexico
Rivera-Tlaltzicapa D.:
Universidad Autónoma MetropolitanaMexico City, Mexico
Francisco-Balderas A.:
Graduate Studies Department, Escuela Superior de Medicina, Instituto Politécnico NacionalMexico City, Mexico
Domínguez-Pérez M.:
Universidad Estatal del Valle de EcatepecMexico City, Mexico
Romero-Morelos P.:
Rheumatology Department, Hospital General de MéxicoMexico City, Mexico
Vázquez-Mellado J.:
Rheumatology Department, Instituto Nacional de Cardiolog:a Ignacio Ch:vezMexico City, Mexico
Silveira L.H.:
Synovial Fluid Laboratory, Instituto Nacional de Rehabilitaci:n LGIIMexico City, Mexico
Pineda C.:
Division of Musculoskeletal and Rheumatic Diseases, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra IbarraMexico City, Mexico
Martínez-Nava G.:
Synovial Fluid Laboratory, Instituto Nacional de Rehabilitaci:n LGIIMexico City, Mexico
Gutierrez M.:
Division of Musculoskeletal and Rheumatic Diseases, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra IbarraMexico City, Mexico
Gold
|